Logo image of PLX

PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis

NYSEARCA:PLX - US74365A3095 - Common Stock

1.64 USD
-0.02 (-1.2%)
Last: 8/25/2025, 9:55:49 AM
Fundamental Rating

5

Overall PLX gets a fundamental rating of 5 out of 10. We evaluated PLX against 547 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

PLX had positive earnings in the past year.
PLX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
In the past 5 years PLX reported 4 times negative operating cash flow.
PLX Yearly Net Income VS EBIT VS OCF VS FCFPLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

PLX has a Return On Assets of 8.00%. This is amongst the best in the industry. PLX outperforms 92.69% of its industry peers.
PLX has a Return On Equity of 12.57%. This is amongst the best in the industry. PLX outperforms 93.42% of its industry peers.
The Return On Invested Capital of PLX (12.68%) is better than 94.88% of its industry peers.
Industry RankSector Rank
ROA 8%
ROE 12.57%
ROIC 12.68%
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLX Yearly ROA, ROE, ROICPLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

With an excellent Profit Margin value of 10.13%, PLX belongs to the best of the industry, outperforming 92.14% of the companies in the same industry.
PLX has a better Operating Margin (13.28%) than 93.78% of its industry peers.
PLX's Gross Margin of 57.53% is fine compared to the rest of the industry. PLX outperforms 77.70% of its industry peers.
In the last couple of years the Gross Margin of PLX has declined.
Industry RankSector Rank
OM 13.28%
PM (TTM) 10.13%
GM 57.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
PLX Yearly Profit, Operating, Gross MarginsPLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PLX is still creating some value.
PLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PLX has more shares outstanding
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLX Yearly Shares OutstandingPLX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLX Yearly Total Debt VS Total AssetsPLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

PLX has an Altman-Z score of -2.26. This is a bad value and indicates that PLX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.26, PLX perfoms like the industry average, outperforming 50.27% of the companies in the same industry.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.26
ROIC/WACC1.24
WACC10.26%
PLX Yearly LT Debt VS Equity VS FCFPLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

PLX has a Current Ratio of 2.72. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
PLX has a worse Current ratio (2.72) than 67.28% of its industry peers.
A Quick Ratio of 1.84 indicates that PLX should not have too much problems paying its short term obligations.
PLX has a Quick ratio of 1.84. This is in the lower half of the industry: PLX underperforms 75.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 1.84
PLX Yearly Current Assets VS Current LiabilitesPLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 135.00% over the past year.
Looking at the last year, PLX shows a very strong growth in Revenue. The Revenue has grown by 62.79%.
The Revenue has been decreasing by -0.48% on average over the past years.
EPS 1Y (TTM)135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)62.79%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%16.21%

3.2 Future

Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 238.30% on average per year.
Based on estimates for the next years, PLX will show a very strong growth in Revenue. The Revenue will grow by 44.15% on average per year.
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PLX Yearly Revenue VS EstimatesPLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
PLX Yearly EPS VS EstimatesPLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 23.43, the valuation of PLX can be described as rather expensive.
93.60% of the companies in the same industry are more expensive than PLX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.24. PLX is around the same levels.
Based on the Price/Forward Earnings ratio of 2.98, the valuation of PLX can be described as very cheap.
99.27% of the companies in the same industry are more expensive than PLX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.81, PLX is valued rather cheaply.
Industry RankSector Rank
PE 23.43
Fwd PE 2.98
PLX Price Earnings VS Forward Price EarningsPLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PLX is valued cheaply inside the industry as 95.61% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 11.93
PLX Per share dataPLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 238.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y328.35%
EPS Next 3Y238.3%

More info and screens

0

5. Dividend

5.1 Amount

PLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (8/25/2025, 9:55:49 AM)

1.64

-0.02 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners11.2%
Inst Owner Change46.32%
Ins Owners4.18%
Ins Owner Change0%
Market Cap130.76M
Analysts80
Price Target14.28 (770.73%)
Short Float %5.09%
Short Ratio4.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40%
EPS NY rev (1m)-58.06%
EPS NY rev (3m)-58.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.57%
Revenue NY rev (1m)-30.59%
Revenue NY rev (3m)-30.59%
Valuation
Industry RankSector Rank
PE 23.43
Fwd PE 2.98
P/S 2.11
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.62
EV/EBITDA 11.93
EPS(TTM)0.07
EY4.27%
EPS(NY)0.55
Fwd EY33.56%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.78
BVpS0.63
TBVpS0.63
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8%
ROE 12.57%
ROCE 15.12%
ROIC 12.68%
ROICexc 18.89%
ROICexgc 18.89%
OM 13.28%
PM (TTM) 10.13%
GM 57.53%
FCFM N/A
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 91.23%
Cap/Sales 2.02%
Interest Coverage 10.74
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 1.84
Altman-Z -2.26
F-Score6
WACC10.26%
ROIC/WACC1.24
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue 1Y (TTM)62.79%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%16.21%
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A